PTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren
SOURCE: PRESS RELEASE VIA PTS THERAPEUTICSPTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis - ACT CF trial missed primary and secondary endpoints -- Company to host conference call today, March 2nd at 9:00 am...